Pfizer says tilrekimig hits Phase 2 atopic dermatitis endpoint with 62.5% EASI-75 at week 16

Bitget2026/10/01 06:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pfizer presented Phase 2 results for tilrekimig in moderate-to-severe atopic dermatitis at the EADV congress.
The study met its main goal, showing more patients reached strong skin clearance than placebo.
Safety looked comparable to placebo, with no serious drug-related events reported.
Pfizer has started Phase 3 trials in atopic dermatitis and asthma, with a Phase 2b/3 study underway in COPD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610010230BIZWIRE_USPR_____20260930_BW032966) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pfizer says tilrekimig hits Phase 2 atopic dermatitis endpoint with 62.5% EASI-75 at week 16

You may also like

Crypto prices